Advanced search
Publication Cover
Infection and Drug Resistance Volume 12, 2019 - Issue
Submit an article Journal homepage
107
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Lower Rates Of Naturally Occurring Resistance-Associated Substitutions (RASs) In Hepatitis C Virus (HCV)-Infected Chronic Kidney Disease (CKD) Patients Than In HCV-Infected Patients With Only Liver Disease

Ekta Gupta1 Department of Clinical Virology, ILBS, New Delhi, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5237-216X
ORCID Icon,
Manish Chandra Choudhary2 Department of Molecular and Cellular Medicine, ILBS, New Delhi, IndiaORCID Iconhttps://orcid.org/0000-0002-3192-7840
ORCID Icon,
Nimisha Upadhyay1 Department of Clinical Virology, ILBS, New Delhi, India
,
Gaurav Singh1 Department of Clinical Virology, ILBS, New Delhi, India
,
Suman Lata Nayak3 Department of Nephrology, ILBS, New Delhi, India
,
Manoj Kumar4 Department of Hepatology, ILBS, New Delhi, India
&
Shiv Kumar Sarin4 Department of Hepatology, ILBS, New Delhi, India
 show all
Pages 3635-3640 | Published online: 22 Nov 2019

References

  • Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19(7):850–858. doi:10.1038/nm.318423836235
  • Vermehren J, Park JS, Jacobson IM, Zeuzem S. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. 2018;69(5):1178–1187. doi:10.1016/j.jhep.2018.07.00230006068
  • Perez AB, Chueca N, Garcia F. Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long? Germs. 2017;7(1):40–44. doi:10.11599/issn.2248-299728331841
  • Ahmed M. Era of direct acting anti-viral agents for the treatment of hepatitis C. World J Hepatol. 2018;10(10):670–684. doi:10.4254/wjh.v10.i10.67030386460
  • Panel A-IHG. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477–1492. doi:10.1093/cid/ciy58530215672
  • Zeuzem S, Mizokami M, Pianko S, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66(5):910–918. doi:10.1016/j.jhep.2017.01.00728108232
  • Cacoub P, Desbois AC, Isnard-Bagnis C, Rocatello D, Ferri C. Hepatitis C virus infection and chronic kidney disease: time for reappraisal. J Hepatol. 2016;65(1 Suppl):S82–S94. doi:10.1016/j.jhep.2016.06.01127641990
  • Fabrizi F, Messa P, Basile C, Martin P. Hepatic disorders in chronic kidney disease. Nat Rev Nephrol. 2010;6(7):395–403. doi:10.1038/nrneph.2010.3720386560
  • Girndt M, Sester U, Sester M, Kaul H, Kohler H. Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant. 1999;14(12):2807–2810. doi:10.1093/ndt/14.12.280710570074
  • Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial. 2007;20(5):440–451. doi:10.1111/j.1525-139X.2007.00283.x17897251
  • National Ethical guidelines for Biomedical and health research involving human participants. Available from: https://www.icmr.nic.in/sites/default/files/guidelines/ICMR_Ethical_Guidelines_2017.pdf. Accessed 917, 2019.
  • Kalaghatgi P, Sikorski AM, Knops E, et al. Geno2pheno[HCV] - a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents. PLoS One. 2016;11(5):e0155869. doi:10.1371/journal.pone.015586927196673
  • Krishnan P, Tripathi R, Schnell G, et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother. 2015;59(9):5445–5454. doi:10.1128/AAC.00998-1526100711
  • Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127–1135. doi:10.1002/hep.v61.425614962
  • Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756–1765. doi:10.1016/S0140-6736(14)61036-925078309
  • Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016;64(2):370–380. doi:10.1002/hep.2846726799692
  • Alves da Silva R, de Souza Todao J, Kamitani FL, et al. Molecular characterization of hepatitis C virus in end-stage renal disease patients under hemodialysis. J Med Virol. 2018;90(3):537–544. doi:10.1002/jmv.v90.329064576
  • Tavares RCF, de Castro Amaral Feldner AC, Pinho JRR, et al. Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus. Infect Drug Resist. 2018;11:1993–2000. doi:10.2147/IDR30464541
  • Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151:70–86. doi:10.1053/j.gastro.2016.04.00327080301

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.